⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MESO News
Mesoblast Limited American Depositary Shares
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
globenewswire.com
MESO
Mesoblast Announces Changes to Board of Directors' Leadership Roles
globenewswire.com
MESO
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
globenewswire.com
MESO
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
prnewswire.com
PROK
MESO
LCTX
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
globenewswire.com
MESO
Mesoblast Participation at Piper Sandler Conference
globenewswire.com
MESO
Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight
globenewswire.com
CYTK
BAYRY
LLY
BCDA
MESO
TNSA
NVO
AZN
BMY
ITCI
JNJ
AMGN
ARWR
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
globenewswire.com
MESO
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
globenewswire.com
MESO
James M. O’Brien Appointed Chief Financial Officer at Mesoblast
globenewswire.com
MESO